Antiretroviral regimens for treatment-experienced patients with HIV-1 infection

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 5, 2008, Pages 687-700

  Lagnese, Meena ^a   Daar, Eric S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretrovirals; HIV; Resistance

Indexed keywords

AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; ENFUVIRTIDE; ETRAVIRINE; INTEGRASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; VICRIVIROC; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; BRAIN HEMORRHAGE; CLINICAL TRIAL; DIARRHEA; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INJECTION SITE REACTION; LIVER TOXICITY; MEDICAL DECISION MAKING; MULTIDRUG RESISTANCE; NAUSEA; PATIENT COMPLIANCE; PEER REVIEW; PNEUMONIA; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS STRAIN; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC;

EID: 41949089788     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.5.687     Document Type: Review

References (55)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60
2. Zaccarelli M, Tozzi V, Lorenzini P, et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005;19:1081-9
3. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004;364:51-62
4. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827-43
5. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 2007 December 1. Available from: http://aidsinfo.nik.gov [Last accessed 29 February 2008]
6. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85
7. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95
8. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006;368:466-75
9. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ ritonavir in treatment-experienced HIV patients: 24-week results of POWER. AIDS 2007;21:395-402
10. Cloret B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-78
11. Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007;46:24-31
12. Katzenstein DA, Bosch RJ, Hellmann N, et al. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS 2003;17:821-30
13. DeGruttola V, Dix L, D'Aquila RT, et al. The relationship between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Ther 2000;5:41-8
14. Madruga JV, Cahn P, Grinsrztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29-38
15. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:39-48
16. Cooper D, Gatell J, Rockstroh J, et al. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus [abstract #105aLB]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25 - 28; Los Angeles, CA
17. Steigbigel R, Kumar P, Eron J, et al. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus [abstract #105bLB]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25 - 28; Los Angeles, CA
18. Nelson M, Fätkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results [abstract #104aLB]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25 - 28; Los Angeles, CA
19. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/ 3 study in the US and Canada [abstract #104bLB]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25 - 28; Los Angeles, CA
20. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007;196:304-12
21. Deeks SG, Hoh R, Neilands TB, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005;192:1537-44
22. Kaufmann D, Pantaleo G, Sudre P, et al. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998;351:723-4
23. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003;349:837-46
24. El-Sadr WM, Lundgren JD, et al. Group Strategies for Management of Antiretroviral Therapy (SMART) Study. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96
25. Campbell TB, Shulman NS, Johnson SC, et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 2005;41:236-42
26. Hatano H, Hunt P, Weidler J, et al. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin Infect Dis 2006;43:1329-36
27. DeJesus E, LaMarca A, Sension M, et al.; The Context Study. Efficacy and safety of GW433908/RTV in PI-experienced subjects with virologic failure (24 week results) [abstract 178]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 9 - 14; Boston, MA
28. Gathe JC Jr, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004;18:1529-37
29. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003;17:2603-14
30. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy fur patients infected with HIV. J Acquir Immune Defic Syndr 2004;36:1011-9
31. Cohen C, Nieto-Cisneros L, Zala C, et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Opin 2005;21:1683-92
32. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19:685-94
33. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006;20:711-8
34. Naeger LK, Struble KA. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients. AIDS 2006;20:847-53
35. Naeger LK, Struble KA. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. AIDS 2007;21:179-85
36. Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007;8:259-64
37. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007;370:49-58
38. Mellors J, Palmer S, Nissley D, et al. Low-frequency NNRTI-resistant variants contribute to failure of efavirenz-containing regimens [abstract 35]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8 - 11; San Francisco, CA
39. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005;79:12773-82
40. Katlama C, Campbell T, Clotet B, et al. DUET-2: 24 week results of a phase III randomized double-blind trial to evaluate the efficacy and safety af TMC125 versus placebo in 591 treatment-experienced HIV-1 infected patients [abstract WESS204:2]. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22 - 25; Sydney, Australia
41. Vingerhoets J, Buelens A, Peeters M, et al. Impact of baseline NNRTI mutations on the virological response to TMC125 in the Phase III clinical trials DUET-1 and DUET-2 [abstract 32]. 16th International HIV Drug Resistance Workshop; 2007 Jun 12 - 16; Barbados, West Indies
42. Harris M, Joy R, Larsen G, et al. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector). AIDS 2006;20:719-23
43. Harris M, Larsen G, Valyi M, et al. Transient neuropathy after needle-free injection outside of recommended sites. AIDS 2006;20:784-5
44. Coakley B, Petropoulos CJ, Whitcomb JM. Assessing chemokine co-receptor usage in HIV. Curr Opin Infect Dis 2005;18:9-15
45. Daar ES, Kesler KL, Petropoulos CJ, et al. Baseline HIV-1 co-receptor tropism predicts disease progression. Clin Infect Dis 2007;45:643-9
46. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005;191:866-72
47. Hunt PW, Harrigan PR, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006;194:926-30
48. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc in antiretroviral-experienced patients infected with CCR5-tropic HIV-1: 48-week results of MOTIVATE 1. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sept 17 - 20; Chicago, IL
49. Mayer H, van Dder Ryst E, Saag M, et al. Safety and efficacy of MARAVIROC (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial [abstract THLB0215]. XVI International AIDS Conference; 2006 Aug 13 - 18; Toronto, Canada
50. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006;80:4909-20
51. Lewis M, Simpson P, Fransen S, et al. CXCR4-using virus detected in patients receiving maraviroc in the phase III studies MOTIVATE 1 and 2 originates from a pre-existing minority of CXCR4-using virus [abstract 56]. 16th International HIV Drug Resistance Workshop; 2007 Jun 12 - 16; Barbados, West Indies
52. Mori J, Mosley M, Lewis M, et al. Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE 2 [abstract 10]. 16th International HIV Drug Resistance Workshop; 2007 Jun 12 - 16; Barbados, West Indies
53. Lim JK, Louie CY, Glaser C, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile Virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008;197:262-5
54. Gulick R, Su Z, Flexner C, et al. ACTG 5211: phase II study of the safety and efficacy of vicriviroc in HIV-infected treatment-experienced subjects [abstract ThLB0217]. XVI International AIDS Conference; 2006 Aug 13 - 18; Toronto, Canada
55. Hazuda DJ, Miller MD, Nguyen BY, Zhao J. Resistance to the HIV integrase inhibitor raltegravir: analysis of Protocol 005, a phase 2 study in patients with triple-class resistant HIV-1 infection [abstract 8]. 16th International HIV Drug Resistance Workshop; 2007 Jun 12 - 16; Barbados, West Indies